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Objective: To improve the compensation for fat atrophy and making the face look young and 
improve the mental and emotional conditions of patients.
Material and methods: Our study was done from April 2003 to March 2006 with an 
  assessment and documentation of the degree of facial lipoatrophy.
Results: We have very good results in 91% of patients with no important complications.
Discussion: Treatment of facial lipoatrophy is justified to overcome the physical and social 
consequences of facial fat loss that occur as a natural part of aging.
Keywords: facial rejuvenation, facial lipoatrophy, aging
Introduction
Facial lipoatrophy is the loss of fat that supports the fullness, shape, and contour of 
the face. However, lipoatrophy is also a common, natural part of the aging process 
and occurs in patients with certain cancers and type 2 diabetes and with extremes of 
exercise.1–3
Treatment options such as bovine- and human-derived collagen products, fat 
  injections, botulinum toxin, hyaluronic acid, and semipermanent fillers are available 
to complement the surgical interventions used by dermasurgeons. The proper selection 
and administration of these agents earlier in the process of lipoatrophy permit derma-
surgeons to tailor the available medical and surgical interventions more effectively to 
meet their patients’ needs. This educational program (education applicants and their 
cooperation with the surgeon and psychologist) will share the clinical experiences of 
an expert faculty on the process of assessing and treating facial lipoatrophy in patients 
who seek counseling. People who are unable to hide their aging appearance can some-
times experience eroded self-image and a lack of self-esteem. In some cases, clinical 
depression and social isolation occur, and among HIV patients, lipoatrophy can lead 
to poor compliance with therapy.4,5
Kligman eloquently stated more than 15 years ago, “An aged, degraded skin is 
uncomfortable to live in. It is also unattractive and leads to aversive reactions by   others. 
The unhandsome aged have trouble maintaining self-esteem when they recollect the 
smooth, unmarked, turgid skin that was the clothing of their youth.”5
Left untreated, elderly individuals, who may already have fewer social contacts 
over time, can be confronted with a further lessening of contact with potential 
  providers of support, including health care providers. Enhancing appearance pro-
vides a   psychological boost that may lead to positive thoughts and actions.5 Most Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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importantly, in HIV patients, treatment in the most severely 
affected patients has been shown to reduce the physical 
consequences of facial fat loss.6 The purpose of this series of 
articles is to review the changes in fat distribution that lead 
to facial lipoatrophy. Clinical strategies to assess lipoatrophy 
and treatment options using temporary and semipermanent 
fillers are also reviewed.
Results
Our study was done on 385 patients in our surgical clinic 
from April 2003 to March 2006. Fat injection for cheek was 
86%, for forehead 10%, and 4% for lip (lower 1%, and upper 
3%). The excellent result for cheek was over 91%   without 
important complications. We used a 3-point scale (mild, 
moderate, or severe) that is commonly used by   clinicians to 
categorize the extent of lipoatrophy. However, by   broadening 
the mild to moderate levels, it is possible to refine this assess-
ment, particularly in patients where the etiology of facial 
lipoatrophy is associated with aging. We used the physical 
appearance of lipoatrophy to create a 4-point scale. A small, 
localized area of fat loss characterizes grade 1 lipoatrophy 
(82%). In grade 2 lipoatrophy (16%), more than one area is 
affected (generally including the jowl and oral commissure). 
Grade 3   lipoatrophy (2%) is characterized by a larger 
area with distinct shadowing. Patients with severe fat 
depletion in all facial regions, and with protruding 
musculature and bones is assigned grade 4   lipoatrophy 
(Table 1 and Figures 1 and 2).
The mean follow-up for the patients in the study was 
6 months and long follow-up was more than 1 year.
Conclusions
Treatment of facial lipoatrophy is justified to overcome the 
physical and social consequences of facial fat loss that occur 
as a natural part of aging or as a consequence of certain 
diseases and drug therapy. During the past 25 years, many 
new treatments have been developed and approved by the 
US Food and Drug Administration (FDA). Other compounds 
and modifications of previously approved compounds are 
being developed and are likely to become available during 
the next few years.
FDA oversight and approval are important because the 
availability of thoroughly tested and approved products offers 
reassurance that a pure formulation can be obtained from a 
reliable source. For best results, physicians must be trained 
and skilled in fat injection techniques and be prepared to 
use a combination of techniques to achieve the best results 
for their patients.
Once lipoatrophy occurs, the goal of treatment is to rees-
tablish the facial arcs and convexities that characterize the 
young face. There are no proven therapies to reverse or   prevent 
peripheral lipoatrophy. Aside from cosmetic surgery, an array 
of temporary, semipermanent, and   permanent injectable fillers 
are available to correct altered fat distribution. Other potential 
options in patients with HIV include switching antiretrovi-
ral drugs and administering thiazolidinediones. The use of 
antioxidants or cofactors has also been suggested.7
Despite the increasing demand and popularity of facial 
rejuvenation procedures, there has been little real change in 
traditional surgical techniques during recent decades.8 Surgi-
cal intervention as a treatment option for facial   lipoatrophy  Figure 1 Before fat injection in grade 3 lipoatrophy.
Figure 2 After fat injection in grade 3 lipoatrophy.
Table 1 Lipoatrophy: 4-point scale
Grade 1 Grade 2 Grade 3 Grade 4
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Facial rejuvenation
produces less than optimal results because it fails to address 
the primary issue of volume loss, and the unwanted results of 
traditional procedures become easy to recognize over time. 
For example, the unopposed tension of lateral vector face-
lifts allows the cheek tissues to descend eventually over the 
tightened jawline, creating a ‘lateral sweep’ or pulled-back 
appearance in the face.8
We offer fat injection instead of other injectable material 
because it is very safe and has no complications.
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